Actively Recruiting
Patient Preference Study Comparing Subcutaneous and Intravenous Immune Checkpoint Inhibitors and Care Delivery Methods for Renal Cell Carcinoma
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-10-16
40
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatment delivery preferences for kidney cancer patients receiving immunotherapy, specifically comparing intravenous and subcutaneous administration methods. The study also aims to assess the practicality of having laboratory tests done at home combined with telehealth visits before treatment days. This Phase 4 trial focuses on patients with renal cell carcinoma who are undergoing standard of care immunotherapy. Participants will be randomly assigned to receive either intravenous or subcutaneous forms of the immune checkpoint inhibitors nivolumab or pembrolizumab. The study includes two parts one comparing patient preference between the delivery methods of these drugs and another comparing preferences between standard care delivery and home lab testing paired with telehealth visits. Treatments and assessments occur over one year. During the study, participants will have their preferences recorded and monitored related to the treatment delivery and care process. Researchers will measure patient preference outcomes over a one-year period. Participants are expected to engage in laboratory tests either at home or at a clinical setting and have telehealth visits prior to treatment days. The trial also involves surveys completed by medical oncologists involved in patient care to gather additional insights.
CONDITIONS
Brief Title
A Study of Treatment Delivery Preference In People With Kidney Cancer
Research Team
S
Sahil Doshi, MD
T
Thomas Atkinson, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here